Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.

ABSTRACT:

Background

About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study aimed to explore the efficacy and safety of dacomitinib, a second-generation EGFR tyrosine kinase inhibitor (EGFR-TKIs), in treating uncommon EGFR-mutated advanced NSCLC.

Methods

Treatment-naïve advanced NSCLC patients treated with dacomitinib at Hunan Cancer Hospital with uncommon EGFR mutations were evaluated. The primary endpoint was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety.

Result

Between December 2019 and December 2021, a total of 16 patients was included. Median PFS was 14.0 (95% CI

SUBMITTER: Pu X 

PROVIDER: S-EPMC10577935 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature